SCHEMBL3455348

SCHEMBL3455348

CCOC(=O)c1nnn(-c2ccccc2F)c1C1CCOCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.50
TP53 P04637 2/20 0.48
ALOX12 P18054 1/20 0.48
ALDH1A1 P00352 5/20 0.46
MAPT P10636 1/20 0.43
SLC5A1 P13866 4/20 0.41
SLC5A2 P31639 4/20 0.41
RXFP1 Q9HBX9 1/20 0.41
HPGD P15428 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
POLB P06746 1/20 0.40
MAPK1 P28482 1/20 0.40
MITF O75030 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3456037 0.96 TP53 (0.47) NPSR1TP53ALOX12ALDH1A1MAPT
SCHEMBL3455812 0.93 NPSR1 (0.55) NPSR1TP53ALOX12ALDH1A1MAPT
SCHEMBL3455998 0.91 NPSR1 (0.53) NPSR1TP53ALOX12ALDH1A1MAPT
SCHEMBL9928680 0.87 TP53 (0.50) NPSR1TP53ALOX12ALDH1A1MAPT
SCHEMBL3758629 0.85 NPSR1 (0.49) NPSR1TP53ALOX12ALDH1A1MAPT
SCHEMBL3456137 0.84 HTT (0.37) ALDH1A1SMN1; SMN2
Bicarbonate SCHEMBL3457190 0.82 NPSR1 (0.46) NPSR1TP53ALOX12ALDH1A1MAPT
SCHEMBL3455921 0.82 TP53 (0.47) NPSR1TP53ALOX12ALDH1A1MAPT
SCHEMBL25767433 0.81 TP53 (0.67) NPSR1TP53ALOX12ALDH1A1MAPT
SCHEMBL3455909 0.79 MEN1 (0.63) NPSR1TP53ALOX12ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2250165-B1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2018-07-25 EP disclosed
US-8202856-B2 Triazole oxadiazoles derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2010-12-02 US disclosed
EP-2250165-A1 TRIAZOLE OXADIAZOLES DERIVATIVES Merck Serono S.A. (CH) 2010-11-17 EP disclosed
WO-2009080663-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO S.A. (CH) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES OXA1L, RO60, PDCD11 NPSR1 1081/4885TP53 2220/4885ALOX12 3234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.